212141-54-3 Usage
Description
Vatalanib base, also known as PTK787, is a member of the phthalazine class of compounds. It is characterized by the replacement of hydrogens at positions 1 and 4 with a p-chlorophenylamino group and a pyridin-4-ylmethyl group, respectively. Vatalanib base is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR, and c-Kit. It has shown potential in various applications due to its unique chemical structure and properties.
Uses
Used in Pharmaceutical Industry:
Vatalanib base is used as an anti-viral agent for its ability to inhibit the activity of various tyrosine kinases, which play a crucial role in the replication and spread of viruses. By targeting these enzymes, Vatalanib base can potentially disrupt the viral life cycle and reduce the severity of viral infections.
Used in Oncology:
Vatalanib base is used as an anti-cancer agent, particularly in the treatment of solid tumors. It works by inhibiting the activity of multiple tyrosine kinases, such as VEGFR, PDGFR, and c-Kit, which are often overexpressed in cancer cells. This inhibition can lead to the suppression of tumor growth, angiogenesis, and metastasis, making it a promising candidate for cancer therapy.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of Vatalanib base, various drug delivery systems have been developed. These systems, which may include organic and metallic nanoparticles, aim to improve the delivery of Vatalanib base to target cells, reducing side effects and increasing therapeutic outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 212141-54-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,2,1,4 and 1 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 212141-54:
(8*2)+(7*1)+(6*2)+(5*1)+(4*4)+(3*1)+(2*5)+(1*4)=73
73 % 10 = 3
So 212141-54-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
212141-54-3Relevant articles and documents
Simple preparation method of vatalanib
-
, (2019/10/01)
The invention provides a simple preparation method of vatalanib. The method comprises the following steps: carrying out a Grignard reaction on 4-halomethylpyridine (III) and metallic magnesium to prepare a corresponding Grignard reagent, carrying out addition on the Grignard reagent and phthalonitrile, condensing the obtained addition product and hydrazine hydrate to prepare 1-amino-4-(pyridin-4-yl)methylpyridazine (IV), and carrying out a substitution reaction on the 1-amino-4-(pyridin-4-yl)methylpyridazine (IV) and 4-halochlorobenzene (V) to obtain the vatalanib (II). The method of the invention has the advantages of small amount of generated wastewater, small toxicity of the raw materials, safety, environmental friendliness, and high safety of the prepared vatalanib; and the finally prepared product has a high purity and a high yield.
COMPOUNDS FOR IMMUNOPOTENTIATION
-
Page/Page column 125-126, (2010/02/15)
Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.
Ocular therapy
-
, (2008/06/13)
A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula: wherein n is 0 to 2, R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl; and Z is unsubstituted or substituted pyridyl, an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom, or a salt thereof.
